The Biden administration expects to take a delivery of 4 million courses of COVID-19 treatments by the end of January, including 265,000 courses of Pfizer Inc.’s newly authorized pill, according to officials familiar with the matter — sharply ramping up therapies for the disease as the omicron variant spreads.
Pfizer’s pill was authorized Wednesday by the Food and Drug Administration, and authorization for Merck & Co.’s pill was also expected this week.
The overall group of treatments includes a monoclonal antibody product, pre-exposure preventive drugs for immunocompromised people, and new antiviral pills, the officials said.